What is the recommended treatment regimen for Churg‑Strauss syndrome (eosinophilic granulomatosis with polyangiitis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Churg-Strauss Syndrome (EGPA)

For severe EGPA (FFS ≥1, peripheral neuropathy, alveolar hemorrhage, or organ-threatening disease), initiate high-dose glucocorticoids combined with cyclophosphamide or rituximab; for non-severe disease, glucocorticoids alone are sufficient for remission induction. 1

Disease Severity Stratification

First, classify disease severity to guide treatment intensity:

Severe EGPA includes:

  • Five-Factor Score (FFS) ≥1 (renal insufficiency, proteinuria, cardiomyopathy, GI involvement, CNS involvement)
  • Peripheral neuropathy
  • Alveolar hemorrhage
  • Other organ- or life-threatening manifestations 1

Non-severe EGPA:

  • FFS = 0
  • Absence of the above severe manifestations 1

Remission Induction Treatment

For Severe Disease (New-Onset)

Glucocorticoid regimen:

  • IV methylprednisolone pulses: 500-1,000 mg daily for 3 days (maximum 3g total)
  • Followed by high-dose oral prednisone: 0.75-1 mg/kg/day 1

Add immunosuppression:

  • Cyclophosphamide: 0.6 g/m² IV pulses every 2 weeks for 1 month, then every 4 weeks. Continue until remission (typically 6 months; up to 9-12 months if slow response) 1
  • OR Rituximab: 1-gram IV pulses 2 weeks apart (equivalent efficacy to cyclophosphamide per REOVAS trial, works regardless of ANCA status) 1

When to choose rituximab over cyclophosphamide:

  • Previous cyclophosphamide exposure/toxicity concerns
  • Patient previously responded to rituximab
  • Cyclophosphamide failure 1

For Non-Severe Disease (New-Onset)

Glucocorticoids alone achieve 93% remission rates 1

  • Start with high-dose oral prednisone (0.75-1 mg/kg/day)
  • Consider adding mepolizumab if glucocorticoid-sparing is priority (300 mg SC every 4 weeks per MIRRA trial) 1

Caveat: 35% experience early relapses (mostly respiratory) within first year, requiring escalation 1

Remission Maintenance Treatment

For Severe EGPA

Glucocorticoids PLUS one or more of: 1

  • Rituximab: 500 mg IV every 6 months (preferred if achieved remission on rituximab; reduces relapse rates to near-zero in observational data) 1
  • Mepolizumab: 300 mg SC every 4 weeks (effective for major organ manifestations including neuropathy/cardiomyopathy) 1
  • Traditional DMARDs: Azathioprine, methotrexate, or leflunomide (routinely used despite limited evidence for relapse prevention) 1

For Non-Severe EGPA

Glucocorticoids alone OR glucocorticoids + mepolizumab 1

  • Mepolizumab particularly beneficial if requiring prednisone ≥7.5 mg/day for asthma control 1

Critical principle: Taper glucocorticoids to minimum effective dose to reduce toxicity 1

Treatment of Relapses

Severe Systemic Relapse

  • High-dose glucocorticoids (IV pulse then oral) + rituximab or cyclophosphamide 1
  • Prefer rituximab if avoiding repeat cyclophosphamide exposure 1

Non-Severe Systemic Relapse

  • Increase glucocorticoid dose
  • Add mepolizumab (300 mg SC every 4 weeks) 1

Respiratory Relapse (Asthma/ENT Only)

Stepwise approach: 1

  1. Optimize inhaled therapies (high-dose inhaled glucocorticoids + long-acting β2-agonists)
  2. Short course high-dose oral prednisone (0.5-1 mg/kg/day for 5-7 days, stop without taper)
  3. Add mepolizumab if inadequate response
  4. Consider functional endoscopic sinus surgery for refractory ENT disease

Refractory Disease Management

Refractory = unchanged/worsening after 4 weeks of appropriate therapy 1

For refractory systemic disease:

  • If failed cyclophosphamide → switch to rituximab
  • If failed rituximab → switch to cyclophosphamide 1

For refractory respiratory disease:

  • Add mepolizumab (300 mg SC every 4 weeks) 1
  • Consider lower dose (100 mg every 4 weeks) for limited respiratory manifestations, titrate up if needed 1
  • Alternative anti-IL-5 agents (benralizumab, reslizumab) if mepolizumab fails 1

Mepolizumab Dosing Specifics

FDA-approved dose: 300 mg SC every 4 weeks 1

Alternative dosing: 100 mg SC every 4 weeks shows comparable efficacy in observational studies, particularly for respiratory-predominant disease; can escalate to 300 mg if response inadequate 1

Indications:

  • Relapsing/refractory non-severe EGPA (proven in MIRRA trial)
  • Maintenance therapy for glucocorticoid-sparing
  • Respiratory relapse management 1

Critical Pitfalls to Avoid

  1. Don't ignore cardiac involvement: ANCA-negative EGPA has higher cardiac risk; obtain echocardiography and cardiac MRI early 2
  2. Don't treat eosinophilia alone as relapse: Requires clinical manifestations 1
  3. Don't use same maintenance for all: Severe disease requires more aggressive maintenance (rituximab/mepolizumab/DMARDs), not just glucocorticoids 1
  4. Don't forget pulmonology/ENT consultation: Respiratory manifestations require specialized inhaled/topical therapies alongside systemic treatment 1
  5. Don't continue high-dose glucocorticoids indefinitely: Glucocorticoid toxicity is major morbidity driver; aggressive tapering with steroid-sparing agents is essential 1

References

Related Questions

What findings can be observed on electrocardiogram (ECG) and echocardiogram in patients with Churg‑Strauss syndrome (eosinophilic granulomatosis with polyangiitis)?
What is the recommended steroid treatment protocol for eosinophilic granulomatosis with polyangiitis (eGPA)?
In Churg‑Strauss syndrome (eosinophilic granulomatosis with polyangiitis), which of the following findings are observed: mononeuritis multiplex, migratory arthritis, pulmonary‑renal syndrome, peripheral eosinophilia, or recurrent aphthous stomatitis?
What are the diagnostic criteria for eosinophilic granulomatosis with polyangiitis?
Do patients with eosinophilic granulomatosis with polyangiitis require trimethoprim‑sulfamethoxazole (cotrimoxazole) prophylaxis, and what does current evidence indicate?
Is topical dutasteride appropriate for a male patient without prostate cancer or severe liver disease for treating male pattern hair loss, and what dosing and monitoring are recommended?
What is myelopathy?
Can migraine be an underlying cause of abdominal pain (abdominal migraine)?
Do vitamin D, magnesium, or berberine affect the efficacy of dehydroepiandrosterone (DHEA) supplementation when taken concurrently?
Can a patient with akathisia after three weeks of aripiprazole (Abilify) 5 mg daily safely stop the dose and switch to lurasidone (Latuda)?
In a patient in their late 80s with a week of worsening abdominal pain, new‑onset dizziness, and a bitter taste in the mouth, what is the appropriate immediate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.